Medytox obtains approval for third botulinum toxin plant in Osong

Medytox received regulatory approval from the Korean Ministry of Food and Drug Safety for its third production plant in Osong, North Chungcheong Province. The plant can produce 600 billion won worth of botulinum toxin products annually and is set to begin commercial production in June 2017.

“The approval of our third plant expands our net production capacity by more than 10 times.”koreaherald.com

• 1 source
• koreaherald.comSohn Ji-youngJun 12, 2017

Summarized from public sources; check the original articles before acting on it.